In the current study, we showed that the combination of regorafenib with CRT0066101 synergistically suppressed the activation of NF-κB pathway in both stimulated CRC cells and under basal conditions (Fig. 5). The gene discussed is NFKB1; the disease is colorectal carcinoma.